{"formatVersion":"1.1","id":"https://www.mentalhealth.com/library/atypical-antidepressants","path":"/library/atypical-antidepressants","url":"https://www.mentalhealth.com/library/atypical-antidepressants","title":"Atypical Antidepressants","family":"Library detail","description":"Atypical antidepressants refer to medications used to treat symptoms of depression if typical antidepressants are ineffective. Find out more here.","language":"en-US","access":{"audience":"public","indexable":true},"provenance":{"sourceUrl":"https://www.mentalhealth.com/library/atypical-antidepressants","wordpressId":"598","contentCompleteness":"complete","dateScope":"original-source"},"authors":[{"@type":"Person","@id":"https://www.mentalhealth.com/people/naomi-carr#person","name":"Naomi Carr","url":"https://www.mentalhealth.com/people/naomi-carr"}],"reviewer":{"@type":"Person","@id":"https://www.mentalhealth.com/people/morgan-blair#person","name":"Morgan Blair","url":"https://www.mentalhealth.com/people/morgan-blair"},"dates":{"datePublished":"2023-09-13T09:52:12Z","dateModified":"2025-08-27T12:44:53Z","lastReviewed":"2023-09-13"},"content":{"html":"<nav aria-label=\"Breadcrumb\" class=\"breadcrumbs\"><ol><li><a href=\"https://www.mentalhealth.com/\">Home</a></li><li><a href=\"https://www.mentalhealth.com/library\">Library</a></li><li><a href=\"https://www.mentalhealth.com/library/medications\">Medications</a></li><li><span aria-current=\"page\">Atypical Antidepressants</span></li></ol></nav><div class=\"article-page article-standard\" data-library-standard=\"\"><div class=\"article-main-grid\"><header class=\"article-heading\"><h1>Atypical Antidepressants</h1><p class=\"article-inline-credits\"><span class=\"credit-row\"><span>Written by <a class=\"article-credit-person\" href=\"https://www.mentalhealth.com/people/naomi-carr\">Naomi Carr</a></span><span>Medically reviewed by <a class=\"article-credit-person\" href=\"https://www.mentalhealth.com/people/morgan-blair\">Morgan Blair, M.A.</a></span></span></p><div class=\"article-dates\"><span>Published on <time datetime=\"2023-09-13T09:52:12Z\">September 13, 2023</time></span><span aria-hidden=\"true\"> · </span><span>Updated on <time datetime=\"2025-08-27T12:44:53Z\">August 27, 2025</time></span></div></header><div class=\"article-jumpbar\"></div><div class=\"article-layout\"><div class=\"article-reading\"><article class=\"prose\" id=\"article-content\"><div class=\"article-intro\" data-source-field=\"hero\"><p>Antidepressants are often used to treat depression, although they may be prescribed to treat other conditions, such as anxiety disorders and insomnia. You might be prescribed an atypical antidepressant if other medications have not been effective or if you have experienced unpleasant side effects from other antidepressants.</p></div><figure class=\"article-feature\"><img alt=\"A healthcare professional explains a medicine bottle to a patient.\" decoding=\"async\" height=\"800\" loading=\"eager\" src=\"https://www.mentalhealth.com/assets/optimized/a009258d21d75ae529af7322.webp\" width=\"1200\" srcset=\"/assets/responsive/5c26904586a2a0fc207e6b13.webp 800w, /assets/optimized/a009258d21d75ae529af7322.webp 1200w\" sizes=\"(max-width: 800px) 100vw, 1200px\"></figure><section aria-labelledby=\"key-takeaways\" class=\"article-takeaways\"><h2 id=\"key-takeaways\">Key takeaways</h2><ul><li>Atypical antidepressants include medications with differing mechanisms that may be considered when other treatments are ineffective or poorly tolerated.</li><li>Individual drugs differ in sedation, appetite effects, and additional uses, so selection depends on a person’s symptoms and risks.</li><li>Monitoring for mood changes, interactions, and withdrawal effects is important when starting, combining, or stopping these medications.</li></ul></section><span id=\"what-are-atypical-antidepressants-there-are-four-classes-of\" class=\"section-anchor-alias\" data-section-alias=\"what-are-atypical-antidepressants\" aria-hidden=\"true\"></span><h2 id=\"what-are-atypical-antidepressants\">What are atypical antidepressants?</h2><p>\nThere are four classes of <a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/antidepressants\">antidepressant medications</a> referred to as typical: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Medications grouped within each of these classes share a similar mechanism of action⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants\" data-reference-link=\"\" aria-label=\"Reference 1: Sheffler, Z.M., Patel, P., &amp; Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.\" data-reference-number=\"1\">[1]</a></sup>.\n</p><p>Antidepressants that don’t fit into any of these classes are referred to as atypical antidepressants. These medications have various and unique mechanisms of action. Because of these differences, atypical antidepressants can be prescribed for treatment-resistant depression, to target specific symptoms, or to avoid undesirable side effects that other medications may cause⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 2: Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>.\n</p><span id=\"types-of-atypical-antidepressants-there-are-several-types-of-atypical-antidepressants-the-fda-has-approved-the-use-of-the-following-atypical-antidepressants-in-the-treatment-of-major-depressive-disorder\" class=\"section-anchor-alias\" data-section-alias=\"types-of-atypical-antidepressants\" aria-hidden=\"true\"></span><h2 id=\"types-of-atypical-antidepressants\">Types of atypical antidepressants</h2><p>\nThere are several types of atypical antidepressants. The FDA has approved the use of the following atypical antidepressants in the treatment of <a href=\"https://www.mentalhealth.com/library/major-depressive-disorder\" class=\"article-inline-link\" data-context-link=\"355\">major depressive disorder</a>⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>:\n</p><ul>\n<li><strong>Bupropion: </strong>Bupropion is available as a tablet and can be prescribed as immediate-release, extended-release, or sustained-release tablets. Brand names include Wellbutrin, Aplenzin, and Zyban.</li>\n<li><strong><a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/trazodone-uses-dosage-side-effects\">Trazodone</a>: </strong>Trazodone is available as a tablet. Brand names include Desyrel and Oleptro.</li>\n<li><strong><a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/mirtazapine-uses-dosage-side-effects\">Mirtazapine</a>: </strong>Mirtazapine is available as a tablet that is swallowed whole and a tablet that disintegrates on the tongue. Brand names include Remeron.</li>\n<li><strong><a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/nefazodone-uses-dosage-side-effects\">Nefazodone</a>: </strong>Nefazodone is available as a tablet. Brand names include Serzone.</li>\n<li><strong><a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/esketamine-uses-dosage-side-effects\">Esketamine</a>: </strong>This medication is administered as a nasal spray. It is available under the brand name Spravato.</li>\n<li><strong>Vortioxetine and <a class=\"article-inline-link\" href=\"https://www.mentalhealth.com/library/vilazodone-uses-dosage-side-effects\">vilazodone</a></strong>: These medications are sometimes listed as SSRIs as they inhibit serotonin reuptake. However, they are also considered atypical as they also have additional actions, unlike other medications in the SSRI Vortioxetine is available as a tablet under the brand name Trintellix. Vilazodone is available as a tablet under the brand name Viibryd⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder\" data-reference-link=\"\" aria-label=\"Reference 4: Alvarez, E., Perez, V., &amp; Artigas, F. (2014). Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder. Neuropsychiatric Disease and Treatment, 10, 1297–1307. dovepress.com.\" data-reference-number=\"4\">[4]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist\" data-reference-link=\"\" aria-label=\"Reference 5: Schwartz, T.L., Siddiqui, U.A., &amp; Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. SAGE Journals. Accessed October 10 2026.\" data-reference-number=\"5\">[5]</a></sup>.</li>\n</ul><span id=\"what-are-atypical-antidepressants-used-to-treat-atypical-antidepressants-are-approved-for-use-in-the-treatment-of-major-depressive-disorder-mdd-many-also-have-other-uses-some-approved-by-the-fda-and-others-prescribed-off-label\" class=\"section-anchor-alias\" data-section-alias=\"what-are-atypical-antidepressants-used-to-treat\" aria-hidden=\"true\"></span><h2 id=\"what-are-atypical-antidepressants-used-to-treat\">What are atypical antidepressants used to treat?</h2><p>\nAtypical antidepressants are approved for use in the treatment of major depressive disorder (MDD). Many also have other uses, some approved by the FDA and others prescribed off-label.\n</p><h3 id=\"bupropion-bupropion-is-approved-by-the-fda-for-use-in-the-treatment-of-mdd-compared-to-other-antidepressants-it-causes-less-sedation-and-fatigue-less-weight-gain-and-less-libido-reduction\">Bupropion</h3><p>\nBupropion is approved by the FDA for use in the treatment of MDD. Compared to other antidepressants, it causes less sedation and fatigue, less weight gain, and less libido reduction⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 2: Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>.\n</p><p>As such, it may be prescribed as an alternative medication for individuals who have experienced these side effects. It can also be prescribed alongside other antidepressants to prevent sexual dysfunction side effects⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults\" data-reference-link=\"\" aria-label=\"Reference 6: le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive.\" data-reference-number=\"6\">[6]</a></sup>.</p><p>Bupropion (Zyban) is approved by the FDA to help with smoking cessation⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 7: GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"7\">[7]</a></sup>.</p><p>\nOff-label uses for bupropion include treating anxiety disorders and attention-deficit/hyperactivity disorder (ADHD)⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults\" data-reference-link=\"\" aria-label=\"Reference 6: le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive.\" data-reference-number=\"6\">[6]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions\" data-reference-link=\"\" aria-label=\"Reference 8: Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., &amp; Tamblyn, R. (2017). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. BMJ, 356, j603. BMJ. Accessed October 10 2026.\" data-reference-number=\"8\">[8]</a></sup>.\n</p><h3 id=\"trazodone-trazodone-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder-compared-to-other-antidepressants-trazodone-causes-fewer-issues-with-sleep-or-sexual-functioning-and-less-anxiety\">Trazodone</h3><p>\nTrazodone is approved by the FDA for use in the treatment of major depressive disorder. Compared to other antidepressants, trazodone causes fewer issues with sleep or sexual functioning and less anxiety⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 2: Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>.\n</p><p>Trazadone is highly sedating, so it is commonly prescribed off-label to treat sleep disorders, such as insomnia. It is more often prescribed for this use than to treat depression, as it can cause unwanted drowsiness⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions\" data-reference-link=\"\" aria-label=\"Reference 8: Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., &amp; Tamblyn, R. (2017). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. BMJ, 356, j603. BMJ. Accessed October 10 2026.\" data-reference-number=\"8\">[8]</a></sup>.</p><p>\nTrazadone is also prescribed off-label to treat anxiety disorders, chronic pain, bulimia nervosa, and schizophrenia⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-uses-trazodone-review\" data-reference-link=\"\" aria-label=\"Reference 9: Bossini, L., Casolaro, I., Koukouna, D., Cecchini, F., &amp; Fagiolini, A. (2012). Off-Label Uses of Trazodone: A Review. Expert Opinion on Pharmacotherapy, 13(12), 1707–1717. Taylor &amp; Francis.\" data-reference-number=\"9\">[9]</a></sup>.\n</p><h3 id=\"mirtazapine-mirtazapine-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder-compared-to-many-other-antidepressants-mirtazapine-begins-working-more-rapidly-and-causes-fewer-side-effects-relating-to-sexual-dysfunction\">Mirtazapine</h3><p>\nMirtazapine is approved by the FDA for use in the treatment of major depressive disorder. Compared to many other antidepressants, mirtazapine begins working more rapidly and causes fewer side effects relating to sexual dysfunction⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 2: Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>.\n</p><p>Mirtazapine is sometimes used off-label to treat sleep disturbances such as insomnia, although trazodone is more commonly prescribed for this⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions\" data-reference-link=\"\" aria-label=\"Reference 8: Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., &amp; Tamblyn, R. (2017). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. BMJ, 356, j603. BMJ. Accessed October 10 2026.\" data-reference-number=\"8\">[8]</a></sup>.</p><p>\nOther off-label uses for mirtazapine include anxiety disorders and obsessive-compulsive disorder (OCD)⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine\" data-reference-link=\"\" aria-label=\"Reference 10: Croom, K.F., Perry, C.M. &amp; Plosker, G.L. (2009). Mirtazapine. CNS Drugs, 23, 427–45. Springer. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>. It may also be used to treat depression in individuals with anorexia nervosa, as it can cause a significant increase in appetite and weight⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine-treatment-adolescent-anorexia-nervosa\" data-reference-link=\"\" aria-label=\"Reference 11: Hrdlicka, M., Beranova, I., Zamecnikova, R. &amp; Urbanek, T. (2008). Mirtazapine in the Treatment of Adolescent Anorexia Nervosa. European Child &amp; Adolescent Psychiatry, 17, 187–189. Springer. Accessed October 10 2026.\" data-reference-number=\"11\">[11]</a></sup>.\n</p><h3 id=\"nefazodone-nefazodone-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder\">Nefazodone</h3><p>\nNefazodone is approved by the FDA for use in the treatment of major depressive disorder⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>.\nNefazodone may be prescribed off-label to treat post-traumatic stress disorder (PTSD)⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults\" data-reference-link=\"\" aria-label=\"Reference 6: le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive.\" data-reference-number=\"6\">[6]</a></sup>.\n</p><h3 id=\"esketamine-esketamine-spravato-is-approved-by-the-fda-for-use-in-the-treatment-of-treatment-resistant-depression-and-major-depressive-disorder-with-acute-suicidal-ideation-it-should-be-used-alongside-an-oral-antidepressant-medication-and-administered-under-professional-supervision\">Esketamine</h3><p>\nEsketamine (Spravato) is approved by the FDA for use in the treatment of treatment-resistant depression and major depressive disorder with acute suicidal ideation. It should be used alongside an oral antidepressant medication and administered under professional supervision⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>.\n</p><h3 id=\"vortioxetine-and-vilazodone-vortioxetine-and-vilazodone-are-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder\">Vortioxetine and Vilazodone</h3><p>\nVortioxetine and vilazodone are approved by the FDA for use in the treatment of major depressive disorder⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>.\n</p><span id=\"how-do-atypical-antidepressants-work-antidepressants-work-by-impacting-the-levels-of-certain-neurotransmitters-in-the-brain-the-neurotransmitters-typically-targeted-by-antidepressants-include\" class=\"section-anchor-alias\" data-section-alias=\"how-do-atypical-antidepressants-work\" aria-hidden=\"true\"></span><h2 id=\"how-do-atypical-antidepressants-work\">How do atypical antidepressants work?</h2><p>\nAntidepressants work by impacting the levels of certain neurotransmitters in the brain. The neurotransmitters typically targeted by antidepressants include⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants\" data-reference-link=\"\" aria-label=\"Reference 1: Sheffler, Z.M., Patel, P., &amp; Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.\" data-reference-number=\"1\">[1]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 2: Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a></sup>:\n</p><ul>\n<li><strong>Serotonin: </strong>Serotonin helps to regulate mood, behavior, libido, sleep, and appetite.</li>\n<li><strong>Dopamine: </strong>Dopamine is involved in the pleasure and reward system in the brain and impacts motivation and decision-making abilities.</li>\n<li><strong>Norepinephrine (also called noradrenaline): </strong>Norepinephrine is involved in the stress response, impacting heart rate and blood pressure. It also affects motor functioning, alertness, and energy levels.</li>\n</ul><h3 id=\"bupropion-bupropion-increases-the-levels-of-dopamine-and-norepinephrine-by-inhibiting-the-reuptake-of-these-neurotransmitters-thus-causing-antidepressant-effects\">Bupropion</h3><p>\nBupropion increases the levels of dopamine and norepinephrine by inhibiting the reuptake of these neurotransmitters, thus causing antidepressant effects⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 7: GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"7\">[7]</a></sup>.\n</p><h3 id=\"trazodone-trazodone-is-a-serotonin-receptor-antagonist-and-reuptake-inhibitor-sari-due-to-its-effects-on-serotonin-activity-trazodone-has-antidepressant-effects-by-increasing-levels-of-serotonin-and-norepinephrine-and-has-sedating-effects-due-to-its-impact-on-histamine-levels\">Trazodone</h3><p>\nTrazodone is a serotonin receptor antagonist and reuptake inhibitor (SARI) due to its effects on serotonin activity. Trazodone has antidepressant effects by increasing levels of serotonin and norepinephrine and has sedating effects due to its impact on histamine levels⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants\" data-reference-link=\"\" aria-label=\"Reference 2: Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.\" data-reference-number=\"2\">[2]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults\" data-reference-link=\"\" aria-label=\"Reference 6: le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive.\" data-reference-number=\"6\">[6]</a></sup>.\n</p><h3 id=\"mirtazapine-mirtazapine-enhances-serotonin-and-norepinephrine-by-working-as-an-antagonist-of-these-neurotransmitter-receptors-thus-causing-antidepressant-effects-it-also-has-some-impact-on-histamine-levels-which-causes-its-sedating-effects\">Mirtazapine</h3><p>\nMirtazapine enhances serotonin and norepinephrine by working as an antagonist of these neurotransmitter receptors, thus causing antidepressant effects. It also has some impact on histamine levels, which causes its sedating effects⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine\" data-reference-link=\"\" aria-label=\"Reference 10: Croom, K.F., Perry, C.M. &amp; Plosker, G.L. (2009). Mirtazapine. CNS Drugs, 23, 427–45. Springer. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>.\n</p><h3 id=\"nefazodone-nefazodone-works-similarly-to-trazodone-and-is-also-a-sari-due-to-its-impact-on-serotonin-however-it-differs-from-trazodone-as-it-has-a-weaker-effect-on-norepinephrine-and-does-not-cause-as-much-sedation\">Nefazodone</h3><p>\nNefazodone works similarly to trazodone and is also a SARI due to its impact on serotonin. However, it differs from trazodone as it has a weaker effect on norepinephrine and does not cause as much sedation⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#acute-effects-nefazodone-trazodone-buspirone-sleep-sleep-related-penile\" data-reference-link=\"\" aria-label=\"Reference 12: Ware, J.C., Rose, F.V., &amp; McBrayer, R.H. (1994). The Acute Effects of Nefazodone, Trazodone and Buspirone on Sleep and Sleep-Related Penile Tumescence in Normal Subjects. Sleep, 17(6), 544–550. Oxford Academic.\" data-reference-number=\"12\">[12]</a></sup>.\n</p><h3 id=\"esketamine-esketamine-is-an-nmda-glutamate-receptor-antagonist-unlike-other-antidepressants-esketamine-impacts-glutamate-levels-and-does-not-affect-serotonin-dopamine-or-norepinephrine-glutamate-is-the-most-abundant-neurotransmitter-in-the-brain-and-affects-mood-learning-memory-and-communication-between-neurons\">Esketamine</h3><p>Esketamine acts as an NMDA receptor antagonist. Under the January 2025 U.S. prescribing information, its nasal spray is approved for treatment-resistant depression in adults either alone or with an oral antidepressant. A separate indication covers depressive symptoms in adults with major depression and acute suicidal thoughts or behavior, together with an oral antidepressant⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#chapter-7-development-new-rapid-action-treatments-mood-disorders\" data-reference-link=\"\" aria-label=\"Reference 13: Janssen Pharmaceuticals, Inc. (2025). SPRAVATO (esketamine) nasal spray: Prescribing information. U.S. Food and Drug Administration. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"13\">[13]</a></sup>.</p><h3 id=\"vortioxetine-and-vilazodone-vortioxetine-and-vilazodone-both-inhibit-serotonin-reuptake-so-they-are-often-considered-selective-serotonin-reuptake-inhibitors-ssris-this-action-increases-serotonin-levels-causing-an-antidepressant-effect-however-unlike-other-ssris-these-medications-also-have-other-neurotransmitter-effects\">Vortioxetine and Vilazodone</h3><p>\nVortioxetine and vilazodone both inhibit serotonin reuptake, so they are often considered selective serotonin reuptake inhibitors (SSRIs). This action increases serotonin levels, causing an antidepressant effect. However, unlike other SSRIs, these medications also have other neurotransmitter effects.\n</p><p>Vortioxetine also impacts several serotoninergic receptors, further influencing serotonin levels, and also affects dopamine and norepinephrine⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder\" data-reference-link=\"\" aria-label=\"Reference 4: Alvarez, E., Perez, V., &amp; Artigas, F. (2014). Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder. Neuropsychiatric Disease and Treatment, 10, 1297–1307. dovepress.com.\" data-reference-number=\"4\">[4]</a></sup>.</p><p>Vilazodone also acts as a partial agonist on a serotoninergic receptor, adding to its effects on serotonin⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist\" data-reference-link=\"\" aria-label=\"Reference 5: Schwartz, T.L., Siddiqui, U.A., &amp; Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. SAGE Journals. Accessed October 10 2026.\" data-reference-number=\"5\">[5]</a></sup>.</p><p>\nBecause of their additional actions, these medications are found to cause fewer side effects commonly seen in SSRIs, such as weight gain and sexual dysfunction⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder\" data-reference-link=\"\" aria-label=\"Reference 4: Alvarez, E., Perez, V., &amp; Artigas, F. (2014). Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder. Neuropsychiatric Disease and Treatment, 10, 1297–1307. dovepress.com.\" data-reference-number=\"4\">[4]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist\" data-reference-link=\"\" aria-label=\"Reference 5: Schwartz, T.L., Siddiqui, U.A., &amp; Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. SAGE Journals. Accessed October 10 2026.\" data-reference-number=\"5\">[5]</a></sup>.\n</p><h2 id=\"atypical-antidepressants-precautions-and-interactions\">Atypical antidepressants precautions and interactions</h2><h3 id=\"suicidal-ideation-many-antidepressants-have-been-found-to-cause-an-increase-in-suicidal-ideation-within-the-first-few-weeks-of-treatment-this-risk-is-particularly-high-in-individuals-under-the-age-of-24-when-this-happens-suicidal-ideation-will-likely-alleviate-within-a-few-months-as-the-medication-takes-effect\">Suicidal ideation</h3><p>\nMany antidepressants have been found to cause an increase in suicidal ideation within the first few weeks of treatment. This risk is particularly high in individuals under the age of 24. When this happens, suicidal ideation will likely alleviate within a few months as the medication takes effect⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants\" data-reference-link=\"\" aria-label=\"Reference 1: Sheffler, Z.M., Patel, P., &amp; Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.\" data-reference-number=\"1\">[1]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>.\n</p><p>If you notice increased thoughts of self-harm or suicide when taking antidepressant medications, it is important to contact your doctor or mental health professional immediately. They can help to ensure your safety and provide appropriate support.\n</p><h3 id=\"pregnancy-and-breastfeeding-it-is-advised-to-consult-with-your-doctor-if-you-are-pregnant-or-planning-to-become-pregnant-while-taking-antidepressant-medication-there-may-be-some-risk-of-fetal-harm-particularly-in-the-third-trimester\">Pregnancy and breastfeeding</h3><p>\nIt is advised to consult with your doctor if you are pregnant or planning to become pregnant while taking antidepressant medication. There may be some risk of fetal harm, particularly in the third trimester⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#trintellix-vortioxetine-tablets\" data-reference-link=\"\" aria-label=\"Reference 14: Takeda Pharmaceuticals America, Inc. (2021). Trintellix (Vortioxetine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"14\">[14]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#viibryd-vilazodone-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 15: Allergan. (2021). Viibryd (Vilazodone Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"15\">[15]</a></sup>. It is essential to be aware of these risks, as well as the potential risks of discontinuing antidepressant treatment, to make an informed decision about medication use.\n</p><p>Similarly, you should consult your doctor if breastfeeding while taking antidepressant medication, as the medicine might be excreted in breast milk. Again, these risks should be weighed against the potential harm of discontinuing treatment⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 7: GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"7\">[7]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 16: Teva Pharmaceuticals. (2014). Trazodone Hydrochloride Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"16\">[16]</a></sup>.</p><p>\nOften, antidepressant use while pregnant or breastfeeding will depend on the individual’s preference, their symptoms, and the severity of their condition. If your condition is moderate to severe, you may be advised to continue your treatment or commence alternative treatment⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>.\n</p><h3 id=\"serotonin-syndrome-serotonin-syndrome-can-occur-when-antidepressant-medications-cause-a-dangerously-high-level-of-serotonin-either-when-used-in-combination-or-alone-serotonin-syndrome-can-cause-symptoms-such-as-agitation-hallucinations-increased-blood-pressure-dizziness-confusion-stomach-issues-and-seizures-and-can-be-fatal-in-some-cases\">Serotonin syndrome</h3><p>\nSerotonin syndrome can occur when antidepressant medications cause a dangerously high level of serotonin, either when used in combination or alone. Serotonin syndrome can cause symptoms such as agitation, hallucinations, increased blood pressure, dizziness, confusion, stomach issues, and seizures, and can be fatal in some cases⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#trintellix-vortioxetine-tablets\" data-reference-link=\"\" aria-label=\"Reference 14: Takeda Pharmaceuticals America, Inc. (2021). Trintellix (Vortioxetine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"14\">[14]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#viibryd-vilazodone-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 15: Allergan. (2021). Viibryd (Vilazodone Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"15\">[15]</a></sup>.\nIf serotonin syndrome occurs, seek medical attention. Antidepressant medication should be stopped immediately and treatment provided⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants\" data-reference-link=\"\" aria-label=\"Reference 1: Sheffler, Z.M., Patel, P., &amp; Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.\" data-reference-number=\"1\">[1]</a></sup>.\n</p><h3 id=\"heart-liver-and-kidney-disease-people-who-have-experienced-cardiac-irregularities-or-heart-liver-or-kidney-disease-should-inform-their-doctor-of-their-medical-history-before-taking-antidepressant-treatment-some-medications-may-be-unsafe-to-take-or-your-doctor-may-wish-to-prescribe-you-a-reduced-dose-and-ensure-careful-monitoring\">Heart, liver, and kidney disease</h3><p>\nPeople who have experienced cardiac irregularities, or heart, liver, or kidney disease, should inform their doctor of their medical history before taking antidepressant treatment. Some medications may be unsafe to take, or your doctor may wish to prescribe you a reduced dose and ensure careful monitoring⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 7: GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"7\">[7]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#viibryd-vilazodone-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 15: Allergan. (2021). Viibryd (Vilazodone Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"15\">[15]</a></sup>.\n</p><h3 id=\"drug-interactions-antidepressants-can-interact-with-several-different-medications-causing-unpleasant-or-dangerous-effects-this-can-include-beta-blockers-anticonvulsants-heart-medications-antivirals-antibiotics-antifungals-steroids-sedatives-other-antidepressants-antipsychotics-blood-thinners-and-st-john-s-wort\">Drug interactions</h3><p>\nAntidepressants can interact with several different medications, causing unpleasant or dangerous effects. This can include beta-blockers, anticonvulsants, heart medications, antivirals, antibiotics, antifungals, steroids, sedatives, other antidepressants, antipsychotics, blood thinners, and St. John’s wort⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 16: Teva Pharmaceuticals. (2014). Trazodone Hydrochloride Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"16\">[16]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#remeron-mirtazapine-tablets\" data-reference-link=\"\" aria-label=\"Reference 17: Schering-Plough. (2007). Remeron (Mirtazapine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"17\">[17]</a></sup>.\n</p><p>It is advised to inform your doctor of all medications and supplements you are using (prescribed or over the counter) before commencing an antidepressant medication.\n</p><h3 id=\"stopping-medication-you-should-never-abruptly-stop-taking-an-antidepressant-medication-as-this-can-cause-unpleasant-withdrawal-symptoms-if-you-wish-to-stop-taking-your-medication-following-your-doctor-s-advice-is-important-as-they-will-likely-gradually-reduce-your-prescription-to-prevent-withdrawal-symptoms\">Stopping medication</h3><p>\nYou should never abruptly stop taking an antidepressant medication, as this can cause unpleasant withdrawal symptoms. If you wish to stop taking your medication, following your doctor’s advice is important, as they will likely gradually reduce your prescription to prevent withdrawal symptoms⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>.\nAdditional precautions include:\n</p><ul>\n<li><strong>Bupropion: </strong>Bupropion can cause an increased risk of seizures, so people should not take it if they have a seizure disorder or are at high risk of seizures, such as those with anorexia or bulimia⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 7: GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"7\">[7]</a></sup>.</li>\n<li><strong>Trazodone: </strong>Trazodone is strongly sedating, so it is advised not to drive while using this medication⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-hydrochloride-tablets\" data-reference-link=\"\" aria-label=\"Reference 16: Teva Pharmaceuticals. (2014). Trazodone Hydrochloride Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"16\">[16]</a></sup>.</li>\n<li><strong>Mirtazapine: </strong>Mirtazapine can cause an increase in appetite and weight⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine\" data-reference-link=\"\" aria-label=\"Reference 10: Croom, K.F., Perry, C.M. &amp; Plosker, G.L. (2009). Mirtazapine. CNS Drugs, 23, 427–45. Springer. Accessed October 10 2026.\" data-reference-number=\"10\">[10]</a></sup>.</li>\n<li><strong>Nefazodone: </strong>Nefazodone can cause significant liver dysfunction that is potentially life-threatening in some cases. It is advised to be aware of and report any concerning symptoms that may indicate liver issues, such as yellowing of the skin, fatigue, and nausea⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants\" data-reference-link=\"\" aria-label=\"Reference 1: Sheffler, Z.M., Patel, P., &amp; Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.\" data-reference-number=\"1\">[1]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a></sup>.</li>\n<li><strong>Esketamine: </strong> This controlled medicine has risks including sedation, dissociation, respiratory depression, and misuse. It is administered under professional supervision through a restricted safety program, with monitoring for at least two hours after each treatment. A clinician determines whether it is appropriate⁠<sup class=\"citation-group\"><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines\" data-reference-link=\"\" aria-label=\"Reference 3: US Food &amp; Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"3\">[3]</a><a class=\"article-citation\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#chapter-7-development-new-rapid-action-treatments-mood-disorders\" data-reference-link=\"\" aria-label=\"Reference 13: Janssen Pharmaceuticals, Inc. (2025). SPRAVATO (esketamine) nasal spray: Prescribing information. U.S. Food and Drug Administration. U.S. Food and Drug Administration. Accessed October 10 2026.\" data-reference-number=\"13\">[13]</a></sup>.</li>\n</ul><section aria-label=\"Subject matter expert\" class=\"article-expert article-expert-inline\" data-expert-kind=\"related\" data-expert-layout=\"standard\"><p class=\"article-bio-role\">Subject matter expert</p><div class=\"article-expert-identity\"><a href=\"https://www.mentalhealth.com/people/leila-khurshid\" class=\"card-identity-photo\" aria-label=\"Leila Khurshid, Pharm.D.\"><img alt=\"\" height=\"64\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/90339bb61ace127cee8df5f2.webp\" width=\"64\" decoding=\"async\"></a><h2><a href=\"https://www.mentalhealth.com/people/leila-khurshid\">Leila Khurshid, Pharm.D.</a></h2></div><p class=\"article-expert-focus\">Clinical pharmacy and medication</p><a href=\"https://www.mentalhealth.com/people/leila-khurshid\" class=\"quiet-button\">View profile</a></section></article><div class=\"article-endmatter\"><section class=\"article-sources\" data-reference-list=\"\" data-reference-style=\"author-date-title-source\" data-source-references=\"\" id=\"references\"><h2 id=\"references-2\">References</h2><ol><li id=\"antidepressants\" value=\"1\" data-reference-number=\"1\" data-reference-format=\"393\">Sheffler, Z.M., Patel, P., &amp; Abdijadid, S. (2023). <em class=\"reference-title\">Antidepressants.</em> In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK538182/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">National Library of Medicine</a>. Accessed October 11 2022.</li><li id=\"atypical-antidepressants\" value=\"2\" data-reference-number=\"2\" data-reference-format=\"393\">Mental Health America. (2023). <em class=\"reference-title\">Atypical Antidepressants.</em> MHA. <a href=\"https://screening.mhanational.org/content/atypical-antidepressants/?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Mental Health America</a>. Accessed October 10 2026.</li><li id=\"depression-medicines\" value=\"3\" data-reference-number=\"3\" data-reference-format=\"393\">US Food &amp; Drug Administration. (2019). <em class=\"reference-title\">Depression Medicines.</em> FDA. <a href=\"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder\" value=\"4\" data-reference-number=\"4\" data-reference-format=\"393\">Alvarez, E., Perez, V., &amp; Artigas, F. (2014). <em class=\"reference-title\">Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder.</em> Neuropsychiatric Disease and Treatment, 10, 1297–1307. <a href=\"http://www.dovepress.com/pharmacology-and-clinical-potential-of-vortioxetine-in-the-treatment-o-peer-reviewed-article-NDT?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">dovepress.com</a>.</li><li id=\"vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist\" value=\"5\" data-reference-number=\"5\" data-reference-format=\"393\">Schwartz, T.L., Siddiqui, U.A., &amp; Stahl, S.M. (2011). <em class=\"reference-title\">Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor.</em> Therapeutic Advances in Psychopharmacology, 1(3), 81–87. <a href=\"https://journals.sagepub.com/doi/10.1177/2045125311409486?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">SAGE Journals</a>. Accessed October 10 2026.</li><li id=\"prescribing-patterns-antidepressants-known-off-label-indications-among-adults\" value=\"6\" data-reference-number=\"6\" data-reference-format=\"393\">le Roux, J.D. (2014). <em class=\"reference-title\">Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University.</em> <a href=\"https://web.archive.org/web/20240326013535/https://citeseerx.ist.psu.edu/document?repid=rep1&amp;type=pdf&amp;doi=c40d8701906afa83c34b7095e2ffcfcb6a28036f&amp;utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Internet Archive</a>.</li><li id=\"wellbutrin-bupropion-hydrochloride-tablets\" value=\"7\" data-reference-number=\"7\" data-reference-format=\"393\">GlaxoSmithKline. (n.d.). <em class=\"reference-title\">Wellbutrin (Bupropion Hydrochloride) Tablets.</em> FDA. <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions\" value=\"8\" data-reference-number=\"8\" data-reference-format=\"393\">Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., &amp; Tamblyn, R. (2017). <em class=\"reference-title\">Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System.</em> BMJ, 356, j603. <a href=\"https://www.bmj.com/content/356/bmj.j603?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">BMJ</a>. Accessed October 10 2026.</li><li id=\"off-label-uses-trazodone-review\" value=\"9\" data-reference-number=\"9\" data-reference-format=\"393\">Bossini, L., Casolaro, I., Koukouna, D., Cecchini, F., &amp; Fagiolini, A. (2012). <em class=\"reference-title\">Off-Label Uses of Trazodone: A Review.</em> Expert Opinion on Pharmacotherapy, 13(12), 1707–1717. <a href=\"https://www.tandfonline.com/doi/full/10.1517/14656566.2012.699523?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Taylor &amp; Francis</a>.</li><li id=\"mirtazapine\" value=\"10\" data-reference-number=\"10\" data-reference-format=\"393\">Croom, K.F., Perry, C.M. &amp; Plosker, G.L. (2009). <em class=\"reference-title\">Mirtazapine.</em> CNS Drugs, 23, 427–45. <a href=\"https://link.springer.com/article/10.2165/00023210-200923050-00006?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Springer</a>. Accessed October 10 2026.</li><li id=\"mirtazapine-treatment-adolescent-anorexia-nervosa\" value=\"11\" data-reference-number=\"11\" data-reference-format=\"393\">Hrdlicka, M., Beranova, I., Zamecnikova, R. &amp; Urbanek, T. (2008). <em class=\"reference-title\">Mirtazapine in the Treatment of Adolescent Anorexia Nervosa.</em> European Child &amp; Adolescent Psychiatry, 17, 187–189. <a href=\"https://link.springer.com/article/10.1007/s00787-007-0670-8?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Springer</a>. Accessed October 10 2026.</li><li id=\"acute-effects-nefazodone-trazodone-buspirone-sleep-sleep-related-penile\" value=\"12\" data-reference-number=\"12\" data-reference-format=\"393\">Ware, J.C., Rose, F.V., &amp; McBrayer, R.H. (1994). <em class=\"reference-title\">The Acute Effects of Nefazodone, Trazodone and Buspirone on Sleep and Sleep-Related Penile Tumescence in Normal Subjects.</em> Sleep, 17(6), 544–550. <a href=\"https://academic.oup.com/sleep/article-lookup/doi/10.1093/sleep/17.6.544?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">Oxford Academic</a>.</li><li id=\"chapter-7-development-new-rapid-action-treatments-mood-disorders\" value=\"13\" data-reference-number=\"13\" data-reference-format=\"393\">Janssen Pharmaceuticals, Inc. (2025). <em class=\"reference-title\">SPRAVATO (esketamine) nasal spray: Prescribing information.</em> U.S. Food and Drug Administration. <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"trintellix-vortioxetine-tablets\" value=\"14\" data-reference-number=\"14\" data-reference-format=\"393\">Takeda Pharmaceuticals America, Inc. (2021). <em class=\"reference-title\">Trintellix (Vortioxetine) Tablets.</em> FDA. <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s021s022lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"viibryd-vilazodone-hydrochloride-tablets\" value=\"15\" data-reference-number=\"15\" data-reference-format=\"393\">Allergan. (2021). <em class=\"reference-title\">Viibryd (Vilazodone Hydrochloride) Tablets.</em> FDA. <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"trazodone-hydrochloride-tablets\" value=\"16\" data-reference-number=\"16\" data-reference-format=\"393\">Teva Pharmaceuticals. (2014). <em class=\"reference-title\">Trazodone Hydrochloride Tablets.</em> FDA. <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li><li id=\"remeron-mirtazapine-tablets\" value=\"17\" data-reference-number=\"17\" data-reference-format=\"393\">Schering-Plough. (2007). <em class=\"reference-title\">Remeron (Mirtazapine) Tablets.</em> FDA. <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-atypical-antidepressants&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"reference-source\">U.S. Food and Drug Administration</a>. Accessed October 10 2026.</li></ol></section><section class=\"article-medical article-panel\"><h2 id=\"medical-content\">Medical Content</h2><p><a href=\"https://www.mentalhealth.com/clinical-affairs\">The Clinical Affairs Team</a> at MentalHealth.com is a dedicated group of medical professionals with diverse and extensive clinical experience. They actively contribute to the development of content, products, and services, and meticulously review all medical material before publication to ensure accuracy and alignment with current research and conversations in mental health. For more information, please visit the <a href=\"https://www.mentalhealth.com/publishing/editorial-policy\">Editorial Policy</a>.</p></section><section class=\"article-about article-panel\"><h2 id=\"about-mentalhealth-com\">About MentalHealth.com</h2><p>MentalHealth.com helps people understand themselves, build healthier relationships, and access the right care. We bring together mental health education, diagnostics, and care management to support well-being throughout every phase of life.</p><div class=\"article-contributors\"><section class=\"article-bio\"><a href=\"https://www.mentalhealth.com/people/naomi-carr\" class=\"card-identity-photo\" aria-label=\"Naomi Carr\"><img alt=\"\" height=\"64\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/47686b37ff1465ff6711c0b5.jpg\" width=\"64\" decoding=\"async\"></a><div><p class=\"article-bio-role\">Author</p><h3 id=\"naomi-carr\"><a href=\"https://www.mentalhealth.com/people/naomi-carr\">Naomi Carr</a></h3><p class=\"article-bio-credentials\">Writer</p><p>Naomi Carr is a writer with a background in English Literature from Oxford Brookes University.</p><dl><div><dt>Published</dt><dd><time datetime=\"2023-09-13T09:52:12Z\">September 13, 2023</time></dd></div><div><dt>Updated</dt><dd><time datetime=\"2025-08-27T12:44:53Z\">August 27, 2025</time></dd></div></dl></div></section><section class=\"article-bio\"><a href=\"https://www.mentalhealth.com/people/morgan-blair\" class=\"card-identity-photo\" aria-label=\"Morgan Blair, M.A.\"><img alt=\"\" height=\"64\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/9f1be5c5cc2b412cfab5f6cc.jpg\" width=\"64\" decoding=\"async\"></a><div><p class=\"article-bio-role\">Medical Reviewer</p><h3 id=\"morgan-blair\"><a href=\"https://www.mentalhealth.com/people/morgan-blair\">Morgan Blair, M.A.</a></h3><p class=\"article-bio-credentials\">MA, LPCC</p><p>Morgan Blair is a licensed therapist, writer and medical reviewer, holding a master’s degree in clinical mental health counseling from Northwestern University.</p><dl><div><dt>Reviewed</dt><dd><time datetime=\"2023-09-13\">September 13, 2023</time></dd></div></dl></div></section></div></section><section aria-label=\"Related community\" class=\"article-topic-community article-topic-community-end\"><a href=\"https://www.mentalhealth.com/community/medications\" class=\"card-identity-photo\" aria-label=\"Medications\"><img alt=\"\" class=\"topic-community-banner\" height=\"675\" loading=\"lazy\" src=\"https://www.mentalhealth.com/assets/optimized/f5e91a4297495afdb6431ec9.webp\" width=\"1199\" decoding=\"async\"></a><p class=\"topic-community-label\">Related community</p><h2><a href=\"https://www.mentalhealth.com/community/medications\">Medications</a></h2><p>Explore questions and perspectives about psychiatric medications and the treatment experience.</p></section></div></div><aside aria-label=\"Article navigation and related information\" class=\"article-sidebar\" data-bounded-rail=\"\" tabindex=\"0\"><details class=\"article-contents\" data-expanded=\"false\" data-scrolled-past=\"false\" data-section-preview=\"3\" open=\"\"><summary><strong>Table of contents</strong><span aria-hidden=\"true\"></span><small data-current-section=\"\">Choose a section</small></summary><nav aria-label=\"Article contents\"><ol id=\"article-section-list\"><li><a aria-label=\"What are atypical antidepressants?\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#what-are-atypical-antidepressants\" title=\"What are atypical antidepressants?\">What are atypical antidepressants?</a></li><li><a aria-label=\"Types of atypical antidepressants\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#types-of-atypical-antidepressants\" title=\"Types of atypical antidepressants\">Types of atypical antidepressants</a></li><li><a aria-label=\"What are atypical antidepressants used to treat?\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#what-are-atypical-antidepressants-used-to-treat\" title=\"What are atypical antidepressants used to treat?\">What are atypical antidepressants used to treat?</a></li><li><a aria-label=\"How do atypical antidepressants work?\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#how-do-atypical-antidepressants-work\" title=\"How do atypical antidepressants work?\">How do atypical antidepressants work?</a></li><li><a aria-label=\"Atypical antidepressants precautions and interactions\" href=\"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants-precautions-and-interactions\" title=\"Atypical antidepressants precautions and interactions\">Atypical antidepressants precautions and interactions</a></li></ol><button aria-controls=\"article-section-list\" aria-expanded=\"false\" class=\"article-sections-toggle\" data-sections-toggle=\"\" type=\"button\">View more</button></nav></details></aside></div></div></div>","text":"Home Library Medications Atypical Antidepressants Atypical Antidepressants Written by Naomi CarrMedically reviewed by Morgan Blair, M.A. Published on September 13, 2023 · Updated on August 27, 2025 Antidepressants are often used to treat depression, although they may be prescribed to treat other conditions, such as anxiety disorders and insomnia. You might be prescribed an atypical antidepressant if other medications have not been effective or if you have experienced unpleasant side effects from other antidepressants. Key takeaways Atypical antidepressants include medications with differing mechanisms that may be considered when other treatments are ineffective or poorly tolerated. Individual drugs differ in sedation, appetite effects, and additional uses, so selection depends on a person’s symptoms and risks. Monitoring for mood changes, interactions, and withdrawal effects is important when starting, combining, or stopping these medications. What are atypical antidepressants? There are four classes of antidepressant medications referred to as typical: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Medications grouped within each of these classes share a similar mechanism of action⁠[1]. Antidepressants that don’t fit into any of these classes are referred to as atypical antidepressants. These medications have various and unique mechanisms of action. Because of these differences, atypical antidepressants can be prescribed for treatment-resistant depression, to target specific symptoms, or to avoid undesirable side effects that other medications may cause⁠[2]. Types of atypical antidepressants There are several types of atypical antidepressants. The FDA has approved the use of the following atypical antidepressants in the treatment of major depressive disorder⁠[3]: Bupropion: Bupropion is available as a tablet and can be prescribed as immediate-release, extended-release, or sustained-release tablets. Brand names include Wellbutrin, Aplenzin, and Zyban. Trazodone: Trazodone is available as a tablet. Brand names include Desyrel and Oleptro. Mirtazapine: Mirtazapine is available as a tablet that is swallowed whole and a tablet that disintegrates on the tongue. Brand names include Remeron. Nefazodone: Nefazodone is available as a tablet. Brand names include Serzone. Esketamine: This medication is administered as a nasal spray. It is available under the brand name Spravato. Vortioxetine and vilazodone: These medications are sometimes listed as SSRIs as they inhibit serotonin reuptake. However, they are also considered atypical as they also have additional actions, unlike other medications in the SSRI Vortioxetine is available as a tablet under the brand name Trintellix. Vilazodone is available as a tablet under the brand name Viibryd⁠[4][5]. What are atypical antidepressants used to treat? Atypical antidepressants are approved for use in the treatment of major depressive disorder (MDD). Many also have other uses, some approved by the FDA and others prescribed off-label. Bupropion Bupropion is approved by the FDA for use in the treatment of MDD. Compared to other antidepressants, it causes less sedation and fatigue, less weight gain, and less libido reduction⁠[2]. As such, it may be prescribed as an alternative medication for individuals who have experienced these side effects. It can also be prescribed alongside other antidepressants to prevent sexual dysfunction side effects⁠[6]. Bupropion (Zyban) is approved by the FDA to help with smoking cessation⁠[7]. Off-label uses for bupropion include treating anxiety disorders and attention-deficit/hyperactivity disorder (ADHD)⁠[6][8]. Trazodone Trazodone is approved by the FDA for use in the treatment of major depressive disorder. Compared to other antidepressants, trazodone causes fewer issues with sleep or sexual functioning and less anxiety⁠[2]. Trazadone is highly sedating, so it is commonly prescribed off-label to treat sleep disorders, such as insomnia. It is more often prescribed for this use than to treat depression, as it can cause unwanted drowsiness⁠[8]. Trazadone is also prescribed off-label to treat anxiety disorders, chronic pain, bulimia nervosa, and schizophrenia⁠[9]. Mirtazapine Mirtazapine is approved by the FDA for use in the treatment of major depressive disorder. Compared to many other antidepressants, mirtazapine begins working more rapidly and causes fewer side effects relating to sexual dysfunction⁠[2]. Mirtazapine is sometimes used off-label to treat sleep disturbances such as insomnia, although trazodone is more commonly prescribed for this⁠[8]. Other off-label uses for mirtazapine include anxiety disorders and obsessive-compulsive disorder (OCD)⁠[10]. It may also be used to treat depression in individuals with anorexia nervosa, as it can cause a significant increase in appetite and weight⁠[11]. Nefazodone Nefazodone is approved by the FDA for use in the treatment of major depressive disorder⁠[3]. Nefazodone may be prescribed off-label to treat post-traumatic stress disorder (PTSD)⁠[6]. Esketamine Esketamine (Spravato) is approved by the FDA for use in the treatment of treatment-resistant depression and major depressive disorder with acute suicidal ideation. It should be used alongside an oral antidepressant medication and administered under professional supervision⁠[3]. Vortioxetine and Vilazodone Vortioxetine and vilazodone are approved by the FDA for use in the treatment of major depressive disorder⁠[3]. How do atypical antidepressants work? Antidepressants work by impacting the levels of certain neurotransmitters in the brain. The neurotransmitters typically targeted by antidepressants include⁠[1][2]: Serotonin: Serotonin helps to regulate mood, behavior, libido, sleep, and appetite. Dopamine: Dopamine is involved in the pleasure and reward system in the brain and impacts motivation and decision-making abilities. Norepinephrine (also called noradrenaline): Norepinephrine is involved in the stress response, impacting heart rate and blood pressure. It also affects motor functioning, alertness, and energy levels. Bupropion Bupropion increases the levels of dopamine and norepinephrine by inhibiting the reuptake of these neurotransmitters, thus causing antidepressant effects⁠[7]. Trazodone Trazodone is a serotonin receptor antagonist and reuptake inhibitor (SARI) due to its effects on serotonin activity. Trazodone has antidepressant effects by increasing levels of serotonin and norepinephrine and has sedating effects due to its impact on histamine levels⁠[2][6]. Mirtazapine Mirtazapine enhances serotonin and norepinephrine by working as an antagonist of these neurotransmitter receptors, thus causing antidepressant effects. It also has some impact on histamine levels, which causes its sedating effects⁠[10]. Nefazodone Nefazodone works similarly to trazodone and is also a SARI due to its impact on serotonin. However, it differs from trazodone as it has a weaker effect on norepinephrine and does not cause as much sedation⁠[12]. Esketamine Esketamine acts as an NMDA receptor antagonist. Under the January 2025 U.S. prescribing information, its nasal spray is approved for treatment-resistant depression in adults either alone or with an oral antidepressant. A separate indication covers depressive symptoms in adults with major depression and acute suicidal thoughts or behavior, together with an oral antidepressant⁠[13]. Vortioxetine and Vilazodone Vortioxetine and vilazodone both inhibit serotonin reuptake, so they are often considered selective serotonin reuptake inhibitors (SSRIs). This action increases serotonin levels, causing an antidepressant effect. However, unlike other SSRIs, these medications also have other neurotransmitter effects. Vortioxetine also impacts several serotoninergic receptors, further influencing serotonin levels, and also affects dopamine and norepinephrine⁠[4]. Vilazodone also acts as a partial agonist on a serotoninergic receptor, adding to its effects on serotonin⁠[5]. Because of their additional actions, these medications are found to cause fewer side effects commonly seen in SSRIs, such as weight gain and sexual dysfunction⁠[4][5]. Atypical antidepressants precautions and interactions Suicidal ideation Many antidepressants have been found to cause an increase in suicidal ideation within the first few weeks of treatment. This risk is particularly high in individuals under the age of 24. When this happens, suicidal ideation will likely alleviate within a few months as the medication takes effect⁠[1][3]. If you notice increased thoughts of self-harm or suicide when taking antidepressant medications, it is important to contact your doctor or mental health professional immediately. They can help to ensure your safety and provide appropriate support. Pregnancy and breastfeeding It is advised to consult with your doctor if you are pregnant or planning to become pregnant while taking antidepressant medication. There may be some risk of fetal harm, particularly in the third trimester⁠[14][15]. It is essential to be aware of these risks, as well as the potential risks of discontinuing antidepressant treatment, to make an informed decision about medication use. Similarly, you should consult your doctor if breastfeeding while taking antidepressant medication, as the medicine might be excreted in breast milk. Again, these risks should be weighed against the potential harm of discontinuing treatment⁠[7][16]. Often, antidepressant use while pregnant or breastfeeding will depend on the individual’s preference, their symptoms, and the severity of their condition. If your condition is moderate to severe, you may be advised to continue your treatment or commence alternative treatment⁠[3]. Serotonin syndrome Serotonin syndrome can occur when antidepressant medications cause a dangerously high level of serotonin, either when used in combination or alone. Serotonin syndrome can cause symptoms such as agitation, hallucinations, increased blood pressure, dizziness, confusion, stomach issues, and seizures, and can be fatal in some cases⁠[14][15]. If serotonin syndrome occurs, seek medical attention. Antidepressant medication should be stopped immediately and treatment provided⁠[1]. Heart, liver, and kidney disease People who have experienced cardiac irregularities, or heart, liver, or kidney disease, should inform their doctor of their medical history before taking antidepressant treatment. Some medications may be unsafe to take, or your doctor may wish to prescribe you a reduced dose and ensure careful monitoring⁠[7][15]. Drug interactions Antidepressants can interact with several different medications, causing unpleasant or dangerous effects. This can include beta-blockers, anticonvulsants, heart medications, antivirals, antibiotics, antifungals, steroids, sedatives, other antidepressants, antipsychotics, blood thinners, and St. John’s wort⁠[16][17]. It is advised to inform your doctor of all medications and supplements you are using (prescribed or over the counter) before commencing an antidepressant medication. Stopping medication You should never abruptly stop taking an antidepressant medication, as this can cause unpleasant withdrawal symptoms. If you wish to stop taking your medication, following your doctor’s advice is important, as they will likely gradually reduce your prescription to prevent withdrawal symptoms⁠[3]. Additional precautions include: Bupropion: Bupropion can cause an increased risk of seizures, so people should not take it if they have a seizure disorder or are at high risk of seizures, such as those with anorexia or bulimia⁠[7]. Trazodone: Trazodone is strongly sedating, so it is advised not to drive while using this medication⁠[16]. Mirtazapine: Mirtazapine can cause an increase in appetite and weight⁠[10]. Nefazodone: Nefazodone can cause significant liver dysfunction that is potentially life-threatening in some cases. It is advised to be aware of and report any concerning symptoms that may indicate liver issues, such as yellowing of the skin, fatigue, and nausea⁠[1][3]. Esketamine: This controlled medicine has risks including sedation, dissociation, respiratory depression, and misuse. It is administered under professional supervision through a restricted safety program, with monitoring for at least two hours after each treatment. A clinician determines whether it is appropriate⁠[3][13]. Subject matter expert Leila Khurshid, Pharm.D. Clinical pharmacy and medication View profile References Sheffler, Z.M., Patel, P., & Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022. Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026. US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Alvarez, E., Perez, V., & Artigas, F. (2014). Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder. Neuropsychiatric Disease and Treatment, 10, 1297–1307. dovepress.com. Schwartz, T.L., Siddiqui, U.A., & Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. SAGE Journals. Accessed October 10 2026. le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive. GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., & Tamblyn, R. (2017). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. BMJ, 356, j603. BMJ. Accessed October 10 2026. Bossini, L., Casolaro, I., Koukouna, D., Cecchini, F., & Fagiolini, A. (2012). Off-Label Uses of Trazodone: A Review. Expert Opinion on Pharmacotherapy, 13(12), 1707–1717. Taylor & Francis. Croom, K.F., Perry, C.M. & Plosker, G.L. (2009). Mirtazapine. CNS Drugs, 23, 427–45. Springer. Accessed October 10 2026. Hrdlicka, M., Beranova, I., Zamecnikova, R. & Urbanek, T. (2008). Mirtazapine in the Treatment of Adolescent Anorexia Nervosa. European Child & Adolescent Psychiatry, 17, 187–189. Springer. Accessed October 10 2026. Ware, J.C., Rose, F.V., & McBrayer, R.H. (1994). The Acute Effects of Nefazodone, Trazodone and Buspirone on Sleep and Sleep-Related Penile Tumescence in Normal Subjects. Sleep, 17(6), 544–550. Oxford Academic. Janssen Pharmaceuticals, Inc. (2025). SPRAVATO (esketamine) nasal spray: Prescribing information. U.S. Food and Drug Administration. U.S. Food and Drug Administration. Accessed October 10 2026. Takeda Pharmaceuticals America, Inc. (2021). Trintellix (Vortioxetine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Allergan. (2021). Viibryd (Vilazodone Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Teva Pharmaceuticals. (2014). Trazodone Hydrochloride Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Schering-Plough. (2007). Remeron (Mirtazapine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026. Medical Content The Clinical Affairs Team at MentalHealth.com is a dedicated group of medical professionals with diverse and extensive clinical experience. They actively contribute to the development of content, products, and services, and meticulously review all medical material before publication to ensure accuracy and alignment with current research and conversations in mental health. For more information, please visit the Editorial Policy. About MentalHealth.com MentalHealth.com helps people understand themselves, build healthier relationships, and access the right care. We bring together mental health education, diagnostics, and care management to support well-being throughout every phase of life. Author Naomi Carr Writer Naomi Carr is a writer with a background in English Literature from Oxford Brookes University. Published September 13, 2023 Updated August 27, 2025 Medical Reviewer Morgan Blair, M.A. MA, LPCC Morgan Blair is a licensed therapist, writer and medical reviewer, holding a master’s degree in clinical mental health counseling from Northwestern University. Reviewed September 13, 2023 Related community Medications Explore questions and perspectives about psychiatric medications and the treatment experience. Table of contentsChoose a section What are atypical antidepressants? Types of atypical antidepressants What are atypical antidepressants used to treat? How do atypical antidepressants work? Atypical antidepressants precautions and interactions View more","wordCount":2338},"schema":{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://www.mentalhealth.com/#organization","name":"MentalHealth.com","url":"https://www.mentalhealth.com/","publishingPrinciples":"https://www.mentalhealth.com/publishing/editorial-policy"},{"@type":"WebSite","@id":"https://www.mentalhealth.com/#website","url":"https://www.mentalhealth.com/","name":"MentalHealth.com","inLanguage":"en-US","publisher":{"@id":"https://www.mentalhealth.com/#organization"}},{"@type":"BreadcrumbList","@id":"https://www.mentalhealth.com/library/atypical-antidepressants#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.mentalhealth.com/"},{"@type":"ListItem","position":2,"name":"Library","item":"https://www.mentalhealth.com/library"},{"@type":"ListItem","position":3,"name":"Medications","item":"https://www.mentalhealth.com/library/medications"},{"@type":"ListItem","position":4,"name":"Atypical Antidepressants","item":"https://www.mentalhealth.com/library/atypical-antidepressants"}]},{"@type":"ImageObject","@id":"https://www.mentalhealth.com/library/atypical-antidepressants#primaryimage","url":"https://www.mentalhealth.com/assets/optimized/a009258d21d75ae529af7322.webp","contentUrl":"https://www.mentalhealth.com/assets/optimized/a009258d21d75ae529af7322.webp","width":1200,"height":800,"encodingFormat":"image/webp","caption":"A healthcare professional explains a medicine bottle to a patient."},{"@type":"Person","@id":"https://www.mentalhealth.com/people/naomi-carr#person","name":"Naomi Carr","url":"https://www.mentalhealth.com/people/naomi-carr","jobTitle":"Writer","image":"https://www.mentalhealth.com/assets/optimized/47686b37ff1465ff6711c0b5.jpg","sameAs":["https://www.linkedin.com/in/naomi-carr-07784590/"],"memberOf":[{"@id":"https://www.mentalhealth.com/publishing#department"}]},{"@type":"Person","@id":"https://www.mentalhealth.com/people/morgan-blair#person","name":"Morgan Blair","url":"https://www.mentalhealth.com/people/morgan-blair","jobTitle":"MA, LPCC","image":"https://www.mentalhealth.com/assets/optimized/9f1be5c5cc2b412cfab5f6cc.jpg","sameAs":["https://www.linkedin.com/in/morgan-blair-5627aa88/"],"memberOf":[{"@id":"https://www.mentalhealth.com/clinical-affairs#department"}]},{"@type":"Article","@id":"https://www.mentalhealth.com/library/atypical-antidepressants#article","url":"https://www.mentalhealth.com/library/atypical-antidepressants","headline":"Atypical Antidepressants","description":"Atypical antidepressants refer to medications used to treat symptoms of depression if typical antidepressants are ineffective. Find out more here.","wordCount":1714,"mainEntityOfPage":{"@id":"https://www.mentalhealth.com/library/atypical-antidepressants#webpage"},"publisher":{"@id":"https://www.mentalhealth.com/#organization"},"articleSection":"Medications","citation":[{"@type":"CreativeWork","name":"Sheffler, Z.M., Patel, P., & Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.","url":"https://www.ncbi.nlm.nih.gov/books/NBK538182/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.","url":"https://screening.mhanational.org/content/atypical-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Alvarez, E., Perez, V., & Artigas, F. (2014). Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder. Neuropsychiatric Disease and Treatment, 10, 1297–1307. dovepress.com.","url":"http://www.dovepress.com/pharmacology-and-clinical-potential-of-vortioxetine-in-the-treatment-o-peer-reviewed-article-NDT?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Schwartz, T.L., Siddiqui, U.A., & Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. SAGE Journals. Accessed October 10 2026.","url":"https://journals.sagepub.com/doi/10.1177/2045125311409486?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive.","url":"https://web.archive.org/web/20240326013535/https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=c40d8701906afa83c34b7095e2ffcfcb6a28036f&utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., & Tamblyn, R. (2017). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. BMJ, 356, j603. BMJ. Accessed October 10 2026.","url":"https://www.bmj.com/content/356/bmj.j603?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Bossini, L., Casolaro, I., Koukouna, D., Cecchini, F., & Fagiolini, A. (2012). Off-Label Uses of Trazodone: A Review. Expert Opinion on Pharmacotherapy, 13(12), 1707–1717. Taylor & Francis.","url":"https://www.tandfonline.com/doi/full/10.1517/14656566.2012.699523?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Croom, K.F., Perry, C.M. & Plosker, G.L. (2009). Mirtazapine. CNS Drugs, 23, 427–45. Springer. Accessed October 10 2026.","url":"https://link.springer.com/article/10.2165/00023210-200923050-00006?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Hrdlicka, M., Beranova, I., Zamecnikova, R. & Urbanek, T. (2008). Mirtazapine in the Treatment of Adolescent Anorexia Nervosa. European Child & Adolescent Psychiatry, 17, 187–189. Springer. Accessed October 10 2026.","url":"https://link.springer.com/article/10.1007/s00787-007-0670-8?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Ware, J.C., Rose, F.V., & McBrayer, R.H. (1994). The Acute Effects of Nefazodone, Trazodone and Buspirone on Sleep and Sleep-Related Penile Tumescence in Normal Subjects. Sleep, 17(6), 544–550. Oxford Academic.","url":"https://academic.oup.com/sleep/article-lookup/doi/10.1093/sleep/17.6.544?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Janssen Pharmaceuticals, Inc. (2025). SPRAVATO (esketamine) nasal spray: Prescribing information. U.S. Food and Drug Administration. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Takeda Pharmaceuticals America, Inc. (2021). Trintellix (Vortioxetine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s021s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Allergan. (2021). Viibryd (Vilazodone Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Teva Pharmaceuticals. (2014). Trazodone Hydrochloride Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Schering-Plough. (2007). Remeron (Mirtazapine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"}],"inLanguage":"en-US","author":[{"@id":"https://www.mentalhealth.com/people/naomi-carr#person"}],"image":{"@id":"https://www.mentalhealth.com/library/atypical-antidepressants#primaryimage"},"about":{"@type":"Thing","@id":"https://www.mentalhealth.com/library/medications#topic","name":"Medications"},"datePublished":"2023-09-13T09:52:12Z","dateModified":"2025-08-27T12:44:53Z"},{"@type":"MedicalWebPage","@id":"https://www.mentalhealth.com/library/atypical-antidepressants#webpage","url":"https://www.mentalhealth.com/library/atypical-antidepressants","name":"Atypical Antidepressants","description":"Atypical antidepressants refer to medications used to treat symptoms of depression if typical antidepressants are ineffective. Find out more here.","inLanguage":"en-US","isPartOf":{"@id":"https://www.mentalhealth.com/library/medications#webpage"},"breadcrumb":{"@id":"https://www.mentalhealth.com/library/atypical-antidepressants#breadcrumb"},"mainEntity":{"@id":"https://www.mentalhealth.com/library/atypical-antidepressants#article"},"relatedLink":["https://www.mentalhealth.com/library/antidepressants","https://www.mentalhealth.com/library/atypical-depression","https://www.mentalhealth.com/library/can-antidepressants-cause-mania","https://www.mentalhealth.com/library/can-antidepressants-change-your-personality","https://www.mentalhealth.com/library/cannabis-and-antidepressants","https://www.mentalhealth.com/people/leila-khurshid"],"publisher":{"@id":"https://www.mentalhealth.com/#organization"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"General public"},"primaryImageOfPage":{"@id":"https://www.mentalhealth.com/library/atypical-antidepressants#primaryimage"},"image":{"@id":"https://www.mentalhealth.com/library/atypical-antidepressants#primaryimage"},"reviewedBy":{"@id":"https://www.mentalhealth.com/people/morgan-blair#person"},"about":{"@type":"Thing","@id":"https://www.mentalhealth.com/library/medications#topic","name":"Medications"},"citation":[{"@type":"CreativeWork","name":"Sheffler, Z.M., Patel, P., & Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.","url":"https://www.ncbi.nlm.nih.gov/books/NBK538182/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.","url":"https://screening.mhanational.org/content/atypical-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Alvarez, E., Perez, V., & Artigas, F. (2014). Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder. Neuropsychiatric Disease and Treatment, 10, 1297–1307. dovepress.com.","url":"http://www.dovepress.com/pharmacology-and-clinical-potential-of-vortioxetine-in-the-treatment-o-peer-reviewed-article-NDT?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Schwartz, T.L., Siddiqui, U.A., & Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. SAGE Journals. Accessed October 10 2026.","url":"https://journals.sagepub.com/doi/10.1177/2045125311409486?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive.","url":"https://web.archive.org/web/20240326013535/https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=c40d8701906afa83c34b7095e2ffcfcb6a28036f&utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., & Tamblyn, R. (2017). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. BMJ, 356, j603. BMJ. Accessed October 10 2026.","url":"https://www.bmj.com/content/356/bmj.j603?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Bossini, L., Casolaro, I., Koukouna, D., Cecchini, F., & Fagiolini, A. (2012). Off-Label Uses of Trazodone: A Review. Expert Opinion on Pharmacotherapy, 13(12), 1707–1717. Taylor & Francis.","url":"https://www.tandfonline.com/doi/full/10.1517/14656566.2012.699523?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Croom, K.F., Perry, C.M. & Plosker, G.L. (2009). Mirtazapine. CNS Drugs, 23, 427–45. Springer. Accessed October 10 2026.","url":"https://link.springer.com/article/10.2165/00023210-200923050-00006?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Hrdlicka, M., Beranova, I., Zamecnikova, R. & Urbanek, T. (2008). Mirtazapine in the Treatment of Adolescent Anorexia Nervosa. European Child & Adolescent Psychiatry, 17, 187–189. Springer. Accessed October 10 2026.","url":"https://link.springer.com/article/10.1007/s00787-007-0670-8?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Ware, J.C., Rose, F.V., & McBrayer, R.H. (1994). The Acute Effects of Nefazodone, Trazodone and Buspirone on Sleep and Sleep-Related Penile Tumescence in Normal Subjects. Sleep, 17(6), 544–550. Oxford Academic.","url":"https://academic.oup.com/sleep/article-lookup/doi/10.1093/sleep/17.6.544?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Janssen Pharmaceuticals, Inc. (2025). SPRAVATO (esketamine) nasal spray: Prescribing information. U.S. Food and Drug Administration. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Takeda Pharmaceuticals America, Inc. (2021). Trintellix (Vortioxetine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s021s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Allergan. (2021). Viibryd (Vilazodone Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Teva Pharmaceuticals. (2014). Trazodone Hydrochloride Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"@type":"CreativeWork","name":"Schering-Plough. (2007). Remeron (Mirtazapine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"}],"datePublished":"2023-09-13T09:52:12Z","dateModified":"2025-08-27T12:44:53Z","lastReviewed":"2023-09-13"}]},"representations":{"html":"https://www.mentalhealth.com/library/atypical-antidepressants","json":"https://www.mentalhealth.com/data/library/atypical-antidepressants.json","jsonLd":"https://www.mentalhealth.com/data/library/atypical-antidepressants.ld.json"},"$schema":"https://www.mentalhealth.com/data/page.schema.json","images":[{"url":"https://www.mentalhealth.com/assets/optimized/a009258d21d75ae529af7322.webp","alt":"A healthcare professional explains a medicine bottle to a patient.","width":1200,"height":800},{"url":"https://www.mentalhealth.com/assets/optimized/90339bb61ace127cee8df5f2.webp","alt":"","width":64,"height":64},{"url":"https://www.mentalhealth.com/assets/optimized/47686b37ff1465ff6711c0b5.jpg","alt":"","width":64,"height":64},{"url":"https://www.mentalhealth.com/assets/optimized/9f1be5c5cc2b412cfab5f6cc.jpg","alt":"","width":64,"height":64},{"url":"https://www.mentalhealth.com/assets/optimized/f5e91a4297495afdb6431ec9.webp","alt":"","width":1199,"height":675}],"sections":[{"id":"key-takeaways","title":"Key takeaways","level":2,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#key-takeaways"},{"id":"what-are-atypical-antidepressants","title":"What are atypical antidepressants?","level":2,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#what-are-atypical-antidepressants"},{"id":"types-of-atypical-antidepressants","title":"Types of atypical antidepressants","level":2,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#types-of-atypical-antidepressants"},{"id":"what-are-atypical-antidepressants-used-to-treat","title":"What are atypical antidepressants used to treat?","level":2,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#what-are-atypical-antidepressants-used-to-treat"},{"id":"bupropion-bupropion-is-approved-by-the-fda-for-use-in-the-treatment-of-mdd-compared-to-other-antidepressants-it-causes-less-sedation-and-fatigue-less-weight-gain-and-less-libido-reduction","title":"Bupropion","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#bupropion-bupropion-is-approved-by-the-fda-for-use-in-the-treatment-of-mdd-compared-to-other-antidepressants-it-causes-less-sedation-and-fatigue-less-weight-gain-and-less-libido-reduction"},{"id":"trazodone-trazodone-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder-compared-to-other-antidepressants-trazodone-causes-fewer-issues-with-sleep-or-sexual-functioning-and-less-anxiety","title":"Trazodone","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-trazodone-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder-compared-to-other-antidepressants-trazodone-causes-fewer-issues-with-sleep-or-sexual-functioning-and-less-anxiety"},{"id":"mirtazapine-mirtazapine-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder-compared-to-many-other-antidepressants-mirtazapine-begins-working-more-rapidly-and-causes-fewer-side-effects-relating-to-sexual-dysfunction","title":"Mirtazapine","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine-mirtazapine-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder-compared-to-many-other-antidepressants-mirtazapine-begins-working-more-rapidly-and-causes-fewer-side-effects-relating-to-sexual-dysfunction"},{"id":"nefazodone-nefazodone-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder","title":"Nefazodone","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#nefazodone-nefazodone-is-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder"},{"id":"esketamine-esketamine-spravato-is-approved-by-the-fda-for-use-in-the-treatment-of-treatment-resistant-depression-and-major-depressive-disorder-with-acute-suicidal-ideation-it-should-be-used-alongside-an-oral-antidepressant-medication-and-administered-under-professional-supervision","title":"Esketamine","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#esketamine-esketamine-spravato-is-approved-by-the-fda-for-use-in-the-treatment-of-treatment-resistant-depression-and-major-depressive-disorder-with-acute-suicidal-ideation-it-should-be-used-alongside-an-oral-antidepressant-medication-and-administered-under-professional-supervision"},{"id":"vortioxetine-and-vilazodone-vortioxetine-and-vilazodone-are-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder","title":"Vortioxetine and Vilazodone","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#vortioxetine-and-vilazodone-vortioxetine-and-vilazodone-are-approved-by-the-fda-for-use-in-the-treatment-of-major-depressive-disorder"},{"id":"how-do-atypical-antidepressants-work","title":"How do atypical antidepressants work?","level":2,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#how-do-atypical-antidepressants-work"},{"id":"bupropion-bupropion-increases-the-levels-of-dopamine-and-norepinephrine-by-inhibiting-the-reuptake-of-these-neurotransmitters-thus-causing-antidepressant-effects","title":"Bupropion","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#bupropion-bupropion-increases-the-levels-of-dopamine-and-norepinephrine-by-inhibiting-the-reuptake-of-these-neurotransmitters-thus-causing-antidepressant-effects"},{"id":"trazodone-trazodone-is-a-serotonin-receptor-antagonist-and-reuptake-inhibitor-sari-due-to-its-effects-on-serotonin-activity-trazodone-has-antidepressant-effects-by-increasing-levels-of-serotonin-and-norepinephrine-and-has-sedating-effects-due-to-its-impact-on-histamine-levels","title":"Trazodone","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-trazodone-is-a-serotonin-receptor-antagonist-and-reuptake-inhibitor-sari-due-to-its-effects-on-serotonin-activity-trazodone-has-antidepressant-effects-by-increasing-levels-of-serotonin-and-norepinephrine-and-has-sedating-effects-due-to-its-impact-on-histamine-levels"},{"id":"mirtazapine-mirtazapine-enhances-serotonin-and-norepinephrine-by-working-as-an-antagonist-of-these-neurotransmitter-receptors-thus-causing-antidepressant-effects-it-also-has-some-impact-on-histamine-levels-which-causes-its-sedating-effects","title":"Mirtazapine","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine-mirtazapine-enhances-serotonin-and-norepinephrine-by-working-as-an-antagonist-of-these-neurotransmitter-receptors-thus-causing-antidepressant-effects-it-also-has-some-impact-on-histamine-levels-which-causes-its-sedating-effects"},{"id":"nefazodone-nefazodone-works-similarly-to-trazodone-and-is-also-a-sari-due-to-its-impact-on-serotonin-however-it-differs-from-trazodone-as-it-has-a-weaker-effect-on-norepinephrine-and-does-not-cause-as-much-sedation","title":"Nefazodone","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#nefazodone-nefazodone-works-similarly-to-trazodone-and-is-also-a-sari-due-to-its-impact-on-serotonin-however-it-differs-from-trazodone-as-it-has-a-weaker-effect-on-norepinephrine-and-does-not-cause-as-much-sedation"},{"id":"esketamine-esketamine-is-an-nmda-glutamate-receptor-antagonist-unlike-other-antidepressants-esketamine-impacts-glutamate-levels-and-does-not-affect-serotonin-dopamine-or-norepinephrine-glutamate-is-the-most-abundant-neurotransmitter-in-the-brain-and-affects-mood-learning-memory-and-communication-between-neurons","title":"Esketamine","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#esketamine-esketamine-is-an-nmda-glutamate-receptor-antagonist-unlike-other-antidepressants-esketamine-impacts-glutamate-levels-and-does-not-affect-serotonin-dopamine-or-norepinephrine-glutamate-is-the-most-abundant-neurotransmitter-in-the-brain-and-affects-mood-learning-memory-and-communication-between-neurons"},{"id":"vortioxetine-and-vilazodone-vortioxetine-and-vilazodone-both-inhibit-serotonin-reuptake-so-they-are-often-considered-selective-serotonin-reuptake-inhibitors-ssris-this-action-increases-serotonin-levels-causing-an-antidepressant-effect-however-unlike-other-ssris-these-medications-also-have-other-neurotransmitter-effects","title":"Vortioxetine and Vilazodone","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#vortioxetine-and-vilazodone-vortioxetine-and-vilazodone-both-inhibit-serotonin-reuptake-so-they-are-often-considered-selective-serotonin-reuptake-inhibitors-ssris-this-action-increases-serotonin-levels-causing-an-antidepressant-effect-however-unlike-other-ssris-these-medications-also-have-other-neurotransmitter-effects"},{"id":"atypical-antidepressants-precautions-and-interactions","title":"Atypical antidepressants precautions and interactions","level":2,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants-precautions-and-interactions"},{"id":"suicidal-ideation-many-antidepressants-have-been-found-to-cause-an-increase-in-suicidal-ideation-within-the-first-few-weeks-of-treatment-this-risk-is-particularly-high-in-individuals-under-the-age-of-24-when-this-happens-suicidal-ideation-will-likely-alleviate-within-a-few-months-as-the-medication-takes-effect","title":"Suicidal ideation","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#suicidal-ideation-many-antidepressants-have-been-found-to-cause-an-increase-in-suicidal-ideation-within-the-first-few-weeks-of-treatment-this-risk-is-particularly-high-in-individuals-under-the-age-of-24-when-this-happens-suicidal-ideation-will-likely-alleviate-within-a-few-months-as-the-medication-takes-effect"},{"id":"pregnancy-and-breastfeeding-it-is-advised-to-consult-with-your-doctor-if-you-are-pregnant-or-planning-to-become-pregnant-while-taking-antidepressant-medication-there-may-be-some-risk-of-fetal-harm-particularly-in-the-third-trimester","title":"Pregnancy and breastfeeding","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#pregnancy-and-breastfeeding-it-is-advised-to-consult-with-your-doctor-if-you-are-pregnant-or-planning-to-become-pregnant-while-taking-antidepressant-medication-there-may-be-some-risk-of-fetal-harm-particularly-in-the-third-trimester"},{"id":"serotonin-syndrome-serotonin-syndrome-can-occur-when-antidepressant-medications-cause-a-dangerously-high-level-of-serotonin-either-when-used-in-combination-or-alone-serotonin-syndrome-can-cause-symptoms-such-as-agitation-hallucinations-increased-blood-pressure-dizziness-confusion-stomach-issues-and-seizures-and-can-be-fatal-in-some-cases","title":"Serotonin syndrome","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#serotonin-syndrome-serotonin-syndrome-can-occur-when-antidepressant-medications-cause-a-dangerously-high-level-of-serotonin-either-when-used-in-combination-or-alone-serotonin-syndrome-can-cause-symptoms-such-as-agitation-hallucinations-increased-blood-pressure-dizziness-confusion-stomach-issues-and-seizures-and-can-be-fatal-in-some-cases"},{"id":"heart-liver-and-kidney-disease-people-who-have-experienced-cardiac-irregularities-or-heart-liver-or-kidney-disease-should-inform-their-doctor-of-their-medical-history-before-taking-antidepressant-treatment-some-medications-may-be-unsafe-to-take-or-your-doctor-may-wish-to-prescribe-you-a-reduced-dose-and-ensure-careful-monitoring","title":"Heart, liver, and kidney disease","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#heart-liver-and-kidney-disease-people-who-have-experienced-cardiac-irregularities-or-heart-liver-or-kidney-disease-should-inform-their-doctor-of-their-medical-history-before-taking-antidepressant-treatment-some-medications-may-be-unsafe-to-take-or-your-doctor-may-wish-to-prescribe-you-a-reduced-dose-and-ensure-careful-monitoring"},{"id":"drug-interactions-antidepressants-can-interact-with-several-different-medications-causing-unpleasant-or-dangerous-effects-this-can-include-beta-blockers-anticonvulsants-heart-medications-antivirals-antibiotics-antifungals-steroids-sedatives-other-antidepressants-antipsychotics-blood-thinners-and-st-john-s-wort","title":"Drug interactions","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#drug-interactions-antidepressants-can-interact-with-several-different-medications-causing-unpleasant-or-dangerous-effects-this-can-include-beta-blockers-anticonvulsants-heart-medications-antivirals-antibiotics-antifungals-steroids-sedatives-other-antidepressants-antipsychotics-blood-thinners-and-st-john-s-wort"},{"id":"stopping-medication-you-should-never-abruptly-stop-taking-an-antidepressant-medication-as-this-can-cause-unpleasant-withdrawal-symptoms-if-you-wish-to-stop-taking-your-medication-following-your-doctor-s-advice-is-important-as-they-will-likely-gradually-reduce-your-prescription-to-prevent-withdrawal-symptoms","title":"Stopping medication","level":3,"url":"https://www.mentalhealth.com/library/atypical-antidepressants#stopping-medication-you-should-never-abruptly-stop-taking-an-antidepressant-medication-as-this-can-cause-unpleasant-withdrawal-symptoms-if-you-wish-to-stop-taking-your-medication-following-your-doctor-s-advice-is-important-as-they-will-likely-gradually-reduce-your-prescription-to-prevent-withdrawal-symptoms"}],"references":[{"number":1,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants","text":"Sheffler, Z.M., Patel, P., & Abdijadid, S. (2023). Antidepressants. In StatPearls [Internet].Treasure Island, FL: StatPearls Publishing. National Library of Medicine. Accessed October 11 2022.","links":[{"url":"https://www.ncbi.nlm.nih.gov/books/NBK538182/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"National Library of Medicine"}],"url":"https://www.ncbi.nlm.nih.gov/books/NBK538182/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":2,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants","text":"Mental Health America. (2023). Atypical Antidepressants. MHA. Mental Health America. Accessed October 10 2026.","links":[{"url":"https://screening.mhanational.org/content/atypical-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Mental Health America"}],"url":"https://screening.mhanational.org/content/atypical-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":3,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","text":"US Food & Drug Administration. (2019). Depression Medicines. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":4,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder","text":"Alvarez, E., Perez, V., & Artigas, F. (2014). Pharmacology and Clinical Potential of Vortioxetine in the Treatment of Major Depressive Disorder. Neuropsychiatric Disease and Treatment, 10, 1297–1307. dovepress.com.","links":[{"url":"http://www.dovepress.com/pharmacology-and-clinical-potential-of-vortioxetine-in-the-treatment-o-peer-reviewed-article-NDT?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"dovepress.com"}],"url":"http://www.dovepress.com/pharmacology-and-clinical-potential-of-vortioxetine-in-the-treatment-o-peer-reviewed-article-NDT?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":5,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist","text":"Schwartz, T.L., Siddiqui, U.A., & Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. SAGE Journals. Accessed October 10 2026.","links":[{"url":"https://journals.sagepub.com/doi/10.1177/2045125311409486?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"SAGE Journals"}],"url":"https://journals.sagepub.com/doi/10.1177/2045125311409486?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":6,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults","text":"le Roux, J.D. (2014). Prescribing Patterns of Antidepressants with Known Off-Label Indications Among Adults.Pennsylvania State University. Internet Archive.","links":[{"url":"https://web.archive.org/web/20240326013535/https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=c40d8701906afa83c34b7095e2ffcfcb6a28036f&utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Internet Archive"}],"url":"https://web.archive.org/web/20240326013535/https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=c40d8701906afa83c34b7095e2ffcfcb6a28036f&utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":7,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets","text":"GlaxoSmithKline. (n.d.). Wellbutrin (Bupropion Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":8,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions","text":"Wong, J., Motulsky, A., Abrahamoqicz, M., McGill, J., Eguale, T., Buckeridge, D.L., & Tamblyn, R. (2017). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. BMJ, 356, j603. BMJ. Accessed October 10 2026.","links":[{"url":"https://www.bmj.com/content/356/bmj.j603?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"BMJ"}],"url":"https://www.bmj.com/content/356/bmj.j603?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":9,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-uses-trazodone-review","text":"Bossini, L., Casolaro, I., Koukouna, D., Cecchini, F., & Fagiolini, A. (2012). Off-Label Uses of Trazodone: A Review. Expert Opinion on Pharmacotherapy, 13(12), 1707–1717. Taylor & Francis.","links":[{"url":"https://www.tandfonline.com/doi/full/10.1517/14656566.2012.699523?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Taylor & Francis"}],"url":"https://www.tandfonline.com/doi/full/10.1517/14656566.2012.699523?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":10,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine","text":"Croom, K.F., Perry, C.M. & Plosker, G.L. (2009). Mirtazapine. CNS Drugs, 23, 427–45. Springer. Accessed October 10 2026.","links":[{"url":"https://link.springer.com/article/10.2165/00023210-200923050-00006?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Springer"}],"url":"https://link.springer.com/article/10.2165/00023210-200923050-00006?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":11,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine-treatment-adolescent-anorexia-nervosa","text":"Hrdlicka, M., Beranova, I., Zamecnikova, R. & Urbanek, T. (2008). Mirtazapine in the Treatment of Adolescent Anorexia Nervosa. European Child & Adolescent Psychiatry, 17, 187–189. Springer. Accessed October 10 2026.","links":[{"url":"https://link.springer.com/article/10.1007/s00787-007-0670-8?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Springer"}],"url":"https://link.springer.com/article/10.1007/s00787-007-0670-8?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":12,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#acute-effects-nefazodone-trazodone-buspirone-sleep-sleep-related-penile","text":"Ware, J.C., Rose, F.V., & McBrayer, R.H. (1994). The Acute Effects of Nefazodone, Trazodone and Buspirone on Sleep and Sleep-Related Penile Tumescence in Normal Subjects. Sleep, 17(6), 544–550. Oxford Academic.","links":[{"url":"https://academic.oup.com/sleep/article-lookup/doi/10.1093/sleep/17.6.544?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Oxford Academic"}],"url":"https://academic.oup.com/sleep/article-lookup/doi/10.1093/sleep/17.6.544?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":13,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#chapter-7-development-new-rapid-action-treatments-mood-disorders","text":"Janssen Pharmaceuticals, Inc. (2025). SPRAVATO (esketamine) nasal spray: Prescribing information. U.S. Food and Drug Administration. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":14,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#trintellix-vortioxetine-tablets","text":"Takeda Pharmaceuticals America, Inc. (2021). Trintellix (Vortioxetine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s021s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s021s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":15,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#viibryd-vilazodone-hydrochloride-tablets","text":"Allergan. (2021). Viibryd (Vilazodone Hydrochloride) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":16,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-hydrochloride-tablets","text":"Teva Pharmaceuticals. (2014). Trazodone Hydrochloride Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"},{"number":17,"id":"https://www.mentalhealth.com/library/atypical-antidepressants#remeron-mirtazapine-tablets","text":"Schering-Plough. (2007). Remeron (Mirtazapine) Tablets. FDA. U.S. Food and Drug Administration. Accessed October 10 2026.","links":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"}],"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com"}],"relatedReading":[],"links":[{"url":"https://www.mentalhealth.com/","label":"Home"},{"url":"https://www.mentalhealth.com/library","label":"Library"},{"url":"https://www.mentalhealth.com/library/medications","label":"Medications"},{"url":"https://www.mentalhealth.com/people/naomi-carr","label":"Naomi Carr"},{"url":"https://www.mentalhealth.com/people/morgan-blair","label":"Morgan Blair, M.A."},{"url":"https://www.mentalhealth.com/library/antidepressants","label":"antidepressant medications"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants","label":"[1]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants","label":"[2]"},{"url":"https://www.mentalhealth.com/library/major-depressive-disorder","label":"major depressive disorder"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/trazodone-uses-dosage-side-effects","label":"Trazodone"},{"url":"https://www.mentalhealth.com/library/mirtazapine-uses-dosage-side-effects","label":"Mirtazapine"},{"url":"https://www.mentalhealth.com/library/nefazodone-uses-dosage-side-effects","label":"Nefazodone"},{"url":"https://www.mentalhealth.com/library/esketamine-uses-dosage-side-effects","label":"Esketamine"},{"url":"https://www.mentalhealth.com/library/vilazodone-uses-dosage-side-effects","label":"vilazodone"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder","label":"[4]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist","label":"[5]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants","label":"[2]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults","label":"[6]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets","label":"[7]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults","label":"[6]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions","label":"[8]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants","label":"[2]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions","label":"[8]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-uses-trazodone-review","label":"[9]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants","label":"[2]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#off-label-indications-antidepressants-primary-care-descriptive-study-prescriptions","label":"[8]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine","label":"[10]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine-treatment-adolescent-anorexia-nervosa","label":"[11]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults","label":"[6]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants","label":"[1]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants","label":"[2]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets","label":"[7]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants","label":"[2]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#prescribing-patterns-antidepressants-known-off-label-indications-among-adults","label":"[6]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine","label":"[10]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#acute-effects-nefazodone-trazodone-buspirone-sleep-sleep-related-penile","label":"[12]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#chapter-7-development-new-rapid-action-treatments-mood-disorders","label":"[13]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder","label":"[4]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist","label":"[5]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#pharmacology-clinical-potential-vortioxetine-treatment-major-depressive-disorder","label":"[4]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#vilazodone-brief-pharmacological-clinical-review-novel-serotonin-partial-agonist","label":"[5]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants","label":"[1]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#trintellix-vortioxetine-tablets","label":"[14]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#viibryd-vilazodone-hydrochloride-tablets","label":"[15]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets","label":"[7]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-hydrochloride-tablets","label":"[16]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#trintellix-vortioxetine-tablets","label":"[14]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#viibryd-vilazodone-hydrochloride-tablets","label":"[15]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants","label":"[1]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets","label":"[7]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#viibryd-vilazodone-hydrochloride-tablets","label":"[15]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-hydrochloride-tablets","label":"[16]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#remeron-mirtazapine-tablets","label":"[17]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#wellbutrin-bupropion-hydrochloride-tablets","label":"[7]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#trazodone-hydrochloride-tablets","label":"[16]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#mirtazapine","label":"[10]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#antidepressants","label":"[1]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#depression-medicines","label":"[3]"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#chapter-7-development-new-rapid-action-treatments-mood-disorders","label":"[13]"},{"url":"https://www.mentalhealth.com/people/leila-khurshid","label":""},{"url":"https://www.mentalhealth.com/people/leila-khurshid","label":"Leila Khurshid, Pharm.D."},{"url":"https://www.mentalhealth.com/people/leila-khurshid","label":"View profile"},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK538182/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"National Library of Medicine"},{"url":"https://screening.mhanational.org/content/atypical-antidepressants/?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Mental Health America"},{"url":"https://www.fda.gov/consumers/womens-health-topics/depression-medicines?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"http://www.dovepress.com/pharmacology-and-clinical-potential-of-vortioxetine-in-the-treatment-o-peer-reviewed-article-NDT?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"dovepress.com"},{"url":"https://journals.sagepub.com/doi/10.1177/2045125311409486?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"SAGE Journals"},{"url":"https://web.archive.org/web/20240326013535/https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=c40d8701906afa83c34b7095e2ffcfcb6a28036f&utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Internet Archive"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.bmj.com/content/356/bmj.j603?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"BMJ"},{"url":"https://www.tandfonline.com/doi/full/10.1517/14656566.2012.699523?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Taylor & Francis"},{"url":"https://link.springer.com/article/10.2165/00023210-200923050-00006?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Springer"},{"url":"https://link.springer.com/article/10.1007/s00787-007-0670-8?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Springer"},{"url":"https://academic.oup.com/sleep/article-lookup/doi/10.1093/sleep/17.6.544?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"Oxford Academic"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s021s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-atypical-antidepressants&utm_source=mentalhealth.com","label":"U.S. Food and Drug Administration"},{"url":"https://www.mentalhealth.com/clinical-affairs","label":"The Clinical Affairs Team"},{"url":"https://www.mentalhealth.com/publishing/editorial-policy","label":"Editorial Policy"},{"url":"https://www.mentalhealth.com/people/naomi-carr","label":""},{"url":"https://www.mentalhealth.com/people/naomi-carr","label":"Naomi Carr"},{"url":"https://www.mentalhealth.com/people/morgan-blair","label":""},{"url":"https://www.mentalhealth.com/people/morgan-blair","label":"Morgan Blair, M.A."},{"url":"https://www.mentalhealth.com/community/medications","label":""},{"url":"https://www.mentalhealth.com/community/medications","label":"Medications"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#what-are-atypical-antidepressants","label":"What are atypical antidepressants?"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#types-of-atypical-antidepressants","label":"Types of atypical antidepressants"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#what-are-atypical-antidepressants-used-to-treat","label":"What are atypical antidepressants used to treat?"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#how-do-atypical-antidepressants-work","label":"How do atypical antidepressants work?"},{"url":"https://www.mentalhealth.com/library/atypical-antidepressants#atypical-antidepressants-precautions-and-interactions","label":"Atypical antidepressants precautions and interactions"}],"seo":{"title":"Atypical Antidepressants: Types, Uses and Precautions","description":"Atypical antidepressants refer to medications used to treat symptoms of depression if typical antidepressants are ineffective. Find out more here.","canonical":"https://www.mentalhealth.com/library/atypical-antidepressants","robots":"index,follow","socialImage":{"url":"https://www.mentalhealth.com/assets/optimized/ec9b0cb47c0207d45e88634d.png","width":1200,"height":630,"alt":"MentalHealth.com — Library","type":"image/png","sitemapGroup":"library"}},"breadcrumbs":[{"name":"Home","url":"https://www.mentalhealth.com/"},{"name":"Library","url":"https://www.mentalhealth.com/library"},{"name":"Medications","url":"https://www.mentalhealth.com/library/medications"},{"name":"Atypical Antidepressants","url":"https://www.mentalhealth.com/library/atypical-antidepressants"}],"subjectMatterExpert":{"name":"Leila Khurshid, Pharm.D.","url":"/people/leila-khurshid","profileId":"2317","topic":"medication","focus":"Clinical pharmacy and medication","selectionBasis":"Documented expertise in the existing published profile","reviewAttribution":false},"keyTakeaways":["Atypical antidepressants include medications with differing mechanisms that may be considered when other treatments are ineffective or poorly tolerated.","Individual drugs differ in sedation, appetite effects, and additional uses, so selection depends on a person’s symptoms and risks.","Monitoring for mood changes, interactions, and withdrawal effects is important when starting, combining, or stopping these medications."],"introduction":{"html":"Antidepressants are often used to treat depression, although they may be prescribed to treat other conditions, such as anxiety disorders and insomnia. You might be prescribed an atypical antidepressant if other medications have not been effective or if you have experienced unpleasant side effects from other antidepressants.","text":"Antidepressants are often used to treat depression, although they may be prescribed to treat other conditions, such as anxiety disorders and insomnia. You might be prescribed an atypical antidepressant if other medications have not been effective or if you have experienced unpleasant side effects from other antidepressants.","sourceField":"hero"},"navigation":[{"label":"What are atypical antidepressants?","href":"#what-are-atypical-antidepressants","heading":"What are atypical antidepressants?"},{"label":"Types of atypical antidepressants","href":"#types-of-atypical-antidepressants","heading":"Types of atypical antidepressants"},{"label":"What are atypical antidepressants used to treat?","href":"#what-are-atypical-antidepressants-used-to-treat","heading":"What are atypical antidepressants used to treat?"},{"label":"How do atypical antidepressants work?","href":"#how-do-atypical-antidepressants-work","heading":"How do atypical antidepressants work?"},{"label":"Atypical antidepressants precautions and interactions","href":"#atypical-antidepressants-precautions-and-interactions","heading":"Atypical antidepressants precautions and interactions"}],"relatedCommunity":{"community":"/community/medications","basis":"topic match"},"referencePresentation":"Numbered author–date references with italic work titles, publication details, linked source names, and documented access dates. Missing publication dates use n.d.","collections":[]}
